Suchergebnisse - "Cronenberger, Carol"

PubPharm (48)

1

Proposing a framework to quantify the potential impact of pharmacokinetic drug-drug interactions caused by a new drug candidate by using real world data about the target patient population

enthalten in: Clinical and translational science | 2024

von Dagenais, S. | Lee, C. | Cronenberger, C. | +2

2

Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population

enthalten in: Clinical and Translational Science | 2024

von Dagenais, S. | Lee, C. | Cronenberger, C. | +2

3

Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis : a phase 3, open-label, randomised, parallel-group study

enthalten in: The Lancet. Rheumatology | 2023

von Fleischmann, R. | Saikali, W. | Lakhanpal, S. | +6

4

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen : Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

enthalten in: Rheumatology and therapy | 2022

von Fleischmann, R. | Bock, A. | Zhang, W. | +4

5

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

enthalten in: Rheumatology and therapy | 2022

von Fleischmann, R. | Bock, A. | Zhang, W. | +4

6

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

enthalten in: Rheumatology and therapy | 2022

von Fleischmann, R. | Bock, A. | Zhang, W. | +4

7

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

enthalten in: Rheumatology and therapy | 2022

von Fleischmann, R. | Bock, A. | Zhang, W. | +4

8

Randomized, Open-Label, Single-Dose, Parallel-Group Pharmacokinetic Study of PF-06410293 (adalimumab-afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects

enthalten in: Clinical pharmacology in drug development | 2021

von Cox, D. | Alvarez, D. | Bock, A. | +1

9

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy : week 52-92 data from a randomized, double-blind, phase 3 trial

enthalten in: Arthritis research & therapy | 2021

von Fleischmann, R. | Alvarez, D. | Bock, A. | +4

10

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

enthalten in: Arthritis Research & Therapy | 2021

von Fleischmann, R. | Alvarez, D. | Bock, A. | +4

1
2
3
4
5
Nächster »
[5]